Jump to content

Dr. Ross Camidge on ALK Inhibitor XALKORI, Who To Screen

Guest LCSC Info

Recommended Posts

Guest LCSC Info

Dr. Ross Camidge on ALK Inhibitor XALKORI, Who To Screen, and Other Therapies for ALK-Positive NSCLC

http://blog.lungevity.org/2011/11/16/dr ... ive-nsclc/

November 16th, 2011 - by Dr. Jack West

Recently, Drs. Ross Camidge and Ben Solomon joined us for a webinar on the subject of “ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC”. Following Dr. Solomon’s great summary of the biology and early clinical experience with the ALK inhibitor XALKORI (crizotinib) in ALK-positive patients (about 4% of the NSCLC population), Dr. Camidge guided us through the practical implications of this work. Specifically, now with a newly FDA-approved therapy of XALKORI tied to a rather uncommon molecular marker, who should we be screening? And since patients who respond to XALKORI appear to become resistant over time, what are the subsequent options for these ALK-positive patients with acquired resistance to XALKORI, or who are unable to get it in the first place?

Click on the blog link above to find the podcast by Dr. Camidge in audio and video formats, as well as the associated transcript and figures.

I’ll soon be posting the question and answer session from this webinar program, which is being edited now. Between now and then, I’ll next be moving from Ross to a newly-identified mutation called ROS-1 and worked on largely by…(can you guess?)

Dr. Ross Camidge — though this mutation is apparently not named for him.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.